Glycorex Transplantation AB (publ)

NGM:GTAB B Stock Report

Market Cap: kr73.6m

Glycorex Transplantation Past Earnings Performance

Past criteria checks 0/6

Glycorex Transplantation's earnings have been declining at an average annual rate of -53.4%, while the Medical Equipment industry saw earnings growing at 6.3% annually. Revenues have been declining at an average rate of 2.8% per year.

Key information

-53.4%

Earnings growth rate

-53.6%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate-2.8%
Return on equity-68.9%
Net Margin-99.7%
Next Earnings Update23 May 2024

Recent past performance updates

Recent updates

Read This Before Buying Glycorex Transplantation AB (publ) (NGM:GTAB B) Shares

Feb 12
Read This Before Buying Glycorex Transplantation AB (publ) (NGM:GTAB B) Shares

How Much Is Glycorex Transplantation's (NGM:GTAB B) CEO Getting Paid?

Dec 21
How Much Is Glycorex Transplantation's (NGM:GTAB B) CEO Getting Paid?

Revenue & Expenses Breakdown
Beta

How Glycorex Transplantation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:GTAB B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2330-30370
30 Sep 2332-16360
30 Jun 2335-11360
31 Mar 2337-9340
31 Dec 2237-9320
30 Sep 2235-11310
30 Jun 2234-10290
31 Mar 2231-11290
31 Dec 2129-12290
30 Sep 2130-11290
30 Jun 2130-9290
31 Mar 2125-14280
31 Dec 2029-8260
30 Sep 2030-5250
30 Jun 2032-2240
31 Mar 20375230
31 Dec 19407240
30 Sep 19417250
30 Jun 19384410
31 Mar 19384350
31 Dec 18383290
30 Sep 1836-12500
30 Jun 1836-13290
31 Mar 1837-14290
31 Dec 1735-16290
30 Sep 1738-1310
30 Jun 1737-1310
31 Mar 1737-1310
31 Dec 16391310
30 Sep 1637-2340
30 Jun 1638-3340
31 Mar 1637-4340
31 Dec 1535-7340
30 Sep 1537-4340
30 Jun 1538-2340
31 Mar 1539-3340
31 Dec 1439-3340
30 Sep 1438-5320
30 Jun 1437-5320
31 Mar 1436-5320
31 Dec 1335-6320
30 Sep 1335-5320
30 Jun 1335-6320

Quality Earnings: GTAB B is currently unprofitable.

Growing Profit Margin: GTAB B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GTAB B is unprofitable, and losses have increased over the past 5 years at a rate of 53.4% per year.

Accelerating Growth: Unable to compare GTAB B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTAB B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (55.1%).


Return on Equity

High ROE: GTAB B has a negative Return on Equity (-68.95%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.